419 related articles for article (PubMed ID: 36982415)
21. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
22. Development and implementation of a prognostic model for clear cell renal cell carcinoma based on heterogeneous TLR4 expression.
Zhou Q; Sun Q; Shen Q; Li X; Qian J
Heliyon; 2024 Feb; 10(4):e25571. PubMed ID: 38380017
[TBL] [Abstract][Full Text] [Related]
23. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma.
Lin H; Fu L; Li P; Zhu J; Xu Q; Wang Y; Mumin MA; Zhou X; Chen Y; Shu G; Yao G; Chen M; Lu J; Zhang L; Liu Y; Zhao Y; Bao J; Chen W; Luo J; Li X; Chen Z; Cao J
J Transl Med; 2023 May; 21(1):343. PubMed ID: 37221577
[TBL] [Abstract][Full Text] [Related]
24. The Expression and Prognostic Value of Co-stimulatory Molecules in Clear Cell Renal Cell Carcinoma (CcRcc).
Wu C; Cai X; He C
Comb Chem High Throughput Screen; 2024; 27(2):335-345. PubMed ID: 37171001
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Model for Clear-cell Renal Cell Carcinoma Based on Natural Killer Cell-related Genes.
Shi X; Yuan M; Yang Y; Wang N; Niu Y; Yang C; Dong A; Zhu H; Jia X
Clin Genitourin Cancer; 2023 Jun; 21(3):e126-e137. PubMed ID: 36513558
[TBL] [Abstract][Full Text] [Related]
26. Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinoma.
Hou S; Gu T; Shi Y; Huang Y; Yao J; Luo P; Cao M; Zhang J; Lin A; Zhu W
Cancer Biomark; 2023; 38(4):489-504. PubMed ID: 38043008
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of CCNB2 and a novel lncRNAs-related risk model predict prognosis in clear cell renal cell carcinoma.
Ren C; Wang Q; Xu Z; Pan Y; Wang S; Liu X
J Cancer Res Clin Oncol; 2024 Feb; 150(2):64. PubMed ID: 38300330
[TBL] [Abstract][Full Text] [Related]
28. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
29. Predicting response of immunotherapy and targeted therapy and prognosis characteristics for renal clear cell carcinoma based on m1A methylation regulators.
Li L; Tan H; Zhou J; Hu F
Sci Rep; 2023 Aug; 13(1):12645. PubMed ID: 37542141
[TBL] [Abstract][Full Text] [Related]
30. Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.
Luo Y; Chen L; Wang G; Xiao Y; Ju L; Wang X
J Cell Biochem; 2019 Aug; 120(8):13751-13764. PubMed ID: 30957284
[TBL] [Abstract][Full Text] [Related]
31. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of a gap junction protein related signature for predicting the prognosis of renal clear cell carcinoma.
Huang Y; Guo W; Zeng Y; Wang X; Fan B; Zhang Y; Yan L; Gu G; Liu Z
Front Oncol; 2024; 14():1354049. PubMed ID: 38454924
[TBL] [Abstract][Full Text] [Related]
34. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
Zhou S; Lu Y; Chen Y; Gan W
Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
[TBL] [Abstract][Full Text] [Related]
35. Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients.
Yang H; Han M; Li H
Front Oncol; 2020; 10():707. PubMed ID: 32432045
[No Abstract] [Full Text] [Related]
36. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract][Full Text] [Related]
39. Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients.
Yao J; Liang Z; Duan L; G Y; Liu J; An G
Heliyon; 2023 Jun; 9(6):e15925. PubMed ID: 37484396
[TBL] [Abstract][Full Text] [Related]
40. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
